Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

NCT07287982 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT07287982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07287982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Lead sponsor
argenx
Phase
Phase 2
Overall status
Recruiting
Start date
December 19, 2025
Completion date
May 28, 2029
Enrollment
60 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy (sma)